About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of LY3314814 in Participants With Liver Impairment

NCT03499041·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Eli Lilly and Company

With

AstraZeneca

Age

18–85

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

\- Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening

You may not be if

Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina
Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation
Have acute unstable neuropsychiatric disease
Have active or uncontrolled neurologic disease, or clinically significant head injury

The record

StatusWithdrawn

PhasePhase 1

Taking part0

StartedJun 2018

UpdatedJun 28, 2018

Conditions

Hepatic Impairment

Where4

Orange County Research Center
Tustin, California, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Orlando Clinical Research Ctr
Orlando, Florida, United States

Clareo Health | A Study of LY3314814 in Participants With Liver Impairment